Retsilisitsoe R Moholisa1, Michael Schomaker, Louise Kuhn, Sandra Castel, Lubbe Wiesner, Ashraf Coovadia, Renate Strehlau, Faeezah Patel, Francoise Pinillos, Elaine J Abrams, Gary Maartens, Helen McIlleron. 1. From the *Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa; †Centre for Infectious Diseases Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; ‡Gertrude H Sergievsky Center, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; §Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; ¶ICAP, Mailman School of Public Health, and College of Physicians & Surgeons, Columbia University, New York, NY; and ‖Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Abstract
BACKGROUND: Adequate exposure to antiretroviral drugs is necessary to achieve and sustain viral suppression. However, the target antiretroviral concentrations associated with long-term viral suppression have not been adequately defined in children. We assessed the relationship between plasma lopinavir or nevirapine concentrations and the risk of subsequent viremia in children initially suppressed on antiretroviral therapy. METHODS: After an induction phase of antiretroviral treatment, 195 children with viral suppression (viral load ≤400 copies/mL) were randomized to continue a lopinavir/ritonavir-based regimen or to switch to a nevirapine-based regimen (together with lamivudine and stavudine). Viral load and lopinavir or nevirapine concentrations were measured at clinic visits 4, 8, 12, 16, 20, 24, 36, 52, 64 and 76 weeks post randomization. Cox multiple failure event models were used to estimate the effects of drug concentrations on the hazard of viremia (viral load >50 copies/mL) RESULTS: : At randomization, the median (interquartile range) age, CD4 T-Lymphocyte percentage, weight-for-age and weight-for-height z scores were 19 (16-24) months, 29% (23-37), -0.6 (-1.3 to 0.2) and -3.2 (-4.1 to -2.1), respectively. The proportion of children with viral load 51-400 copies/mL at randomization was 43%. The hazard of subsequent viremia during follow-up was increased for lopinavir concentrations <1 versus ≥1 mg/L [adjusted hazard ratio 0.62 (95% confidence interval, 0.40-0.94)] and for children with viral loads 51-400 copies/mL at randomization. Nevirapine concentrations were not significantly associated with subsequent viremia. CONCLUSIONS: Plasma lopinavir concentrations predicted viral outcomes in children receiving lopinavir-based antiretroviral therapy. Our findings support a minimum target concentration of ≥1 mg/L of lopinavir to ensure sustained viral suppression.
RCT Entities:
BACKGROUND: Adequate exposure to antiretroviral drugs is necessary to achieve and sustain viral suppression. However, the target antiretroviral concentrations associated with long-term viral suppression have not been adequately defined in children. We assessed the relationship between plasma lopinavir or nevirapine concentrations and the risk of subsequent viremia in children initially suppressed on antiretroviral therapy. METHODS: After an induction phase of antiretroviral treatment, 195 children with viral suppression (viral load ≤400 copies/mL) were randomized to continue a lopinavir/ritonavir-based regimen or to switch to a nevirapine-based regimen (together with lamivudine and stavudine). Viral load and lopinavir or nevirapine concentrations were measured at clinic visits 4, 8, 12, 16, 20, 24, 36, 52, 64 and 76 weeks post randomization. Cox multiple failure event models were used to estimate the effects of drug concentrations on the hazard of viremia (viral load >50 copies/mL) RESULTS: : At randomization, the median (interquartile range) age, CD4 T-Lymphocyte percentage, weight-for-age and weight-for-height z scores were 19 (16-24) months, 29% (23-37), -0.6 (-1.3 to 0.2) and -3.2 (-4.1 to -2.1), respectively. The proportion of children with viral load 51-400 copies/mL at randomization was 43%. The hazard of subsequent viremia during follow-up was increased for lopinavir concentrations <1 versus ≥1 mg/L [adjusted hazard ratio 0.62 (95% confidence interval, 0.40-0.94)] and for children with viral loads 51-400 copies/mL at randomization. Nevirapine concentrations were not significantly associated with subsequent viremia. CONCLUSIONS: Plasma lopinavir concentrations predicted viral outcomes in children receiving lopinavir-based antiretroviral therapy. Our findings support a minimum target concentration of ≥1 mg/L of lopinavir to ensure sustained viral suppression.
Authors: D González de Requena; S Bonora; S Garazzino; M Sciandra; A D'Avolio; R Raiteri; R Marrone; M Boffito; F G De Rosa; A Sinicco; G Di Perri Journal: Antimicrob Agents Chemother Date: 2005-09 Impact factor: 5.191
Authors: Honghu Liu; Loren G Miller; Ron D Hays; Carol E Golin; Tongtong Wu; Neil S Wenger; Andrew H Kaplan Journal: J Acquir Immune Defic Syndr Date: 2006-03 Impact factor: 3.731
Authors: Natella Y Rakhmanina; John N van den Anker; Steven J Soldin; Ron H van Schaik; Nick Mordwinkin; Michael N Neely Journal: Ther Drug Monit Date: 2010-06 Impact factor: 3.681
Authors: Shahin Lockman; Michael D Hughes; James McIntyre; Yu Zheng; Tsungai Chipato; Francesca Conradie; Fred Sawe; Aida Asmelash; Mina C Hosseinipour; Lerato Mohapi; Elizabeth Stringer; Rosie Mngqibisa; Abraham Siika; Diana Atwine; James Hakim; Douglas Shaffer; Cecilia Kanyama; Kara Wools-Kaloustian; Robert A Salata; Evelyn Hogg; Beverly Alston-Smith; Ann Walawander; Eva Purcelle-Smith; Susan Eshleman; James Rooney; Sibtain Rahim; John W Mellors; Robert T Schooley; Judith S Currier Journal: N Engl J Med Date: 2010-10-14 Impact factor: 91.245
Authors: F Van Leth; B S Kappelhoff; D Johnson; M H Losso; A Boron-Kaczmarska; M S Saag; J-M Livrozet; D B Hall; J Leith; A D R Huitema; F W Wit; J H Beijnen; J M A Lange Journal: AIDS Res Hum Retroviruses Date: 2006-03 Impact factor: 2.205
Authors: Monica Gandhi; Rajesh T Gandhi; Andrei Stefanescu; Ronald J Bosch; Joshua C Cyktor; Howard Horng; Alexander Louie; Nhi Phung; Joseph J Eron; Evelyn Hogg; Bernard J C Macatangay; Christopher Hensel; Courtney V Fletcher; John W Mellors; Deborah K McMahon Journal: J Infect Dis Date: 2018-06-20 Impact factor: 5.226
Authors: Jose R Castillo-Mancilla; Johnathan A Edwards; Jaysingh Brijkumar; Mahomed-Yunus Moosa; Yuan Zhao; Igho Ofotokun; Brent A Johnson; Mitchell H Lee; Selvan Pillay; Melendhran Pillay; Pravi Moodley; Daniel R Kuritzkes; Henry Sunpath; Lane R Bushman; Lucas Ellison; Peter L Anderson; Vincent C Marconi Journal: J Int AIDS Soc Date: 2021-12 Impact factor: 5.396